Table 4

Distribution of AML96 DSIL patients with the GFI136S or GFI136N form, respectively, in morphological AML subtypes as defined in the FAB classification

FAB subgroupGFI136S% (no. of all cases)GFI1S36N% (no. of all cases)P
M0 (17) 88 (15) 12 (2) .69 
M1 (79) 90 (71) 10 (8) 
M2 (132) 89 (117) 11 (15) .723 
M4 (48) 98 (47) 2 (1) .046 
M4eo (21) 91 (19) 10 (2) 
M5a (51) 92 (47) 8 (4) .629 
M5b (14) 71 (10) 29 (4) .043 
M6 (8) 75 (6) 25 (2) .197 
M7 (4) 75 (3) 25 (1) .355 
RAEB-T (2) 100 (2) 
Total (377) 89 11  
FAB subgroupGFI136S% (no. of all cases)GFI1S36N% (no. of all cases)P
M0 (17) 88 (15) 12 (2) .69 
M1 (79) 90 (71) 10 (8) 
M2 (132) 89 (117) 11 (15) .723 
M4 (48) 98 (47) 2 (1) .046 
M4eo (21) 91 (19) 10 (2) 
M5a (51) 92 (47) 8 (4) .629 
M5b (14) 71 (10) 29 (4) .043 
M6 (8) 75 (6) 25 (2) .197 
M7 (4) 75 (3) 25 (1) .355 
RAEB-T (2) 100 (2) 
Total (377) 89 11  

By the use of a mosaic analysis, no significant difference could be observed between patients carrying the 2 GFI1 variants.

AML indicates acute myeloid leukemia; DSIL, Deutsche Studieninitiative Leukämie; FAB, French-American-British; and GFI1, Growth Factor Independence 1.

Close Modal

or Create an Account

Close Modal
Close Modal